
AbbVie Inc. (NYSE:ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor.
Upper limb essential tremor is a progressive movement disorder characterized by rhythmic, involuntary shaking of the hands and arms, most pronounced during action or specific postures.